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Urinary excretion of endothelin-l in normal subjects and patients with 
renal disease. To elucidate the pathophysiological significance of uri-
nary endothelin-l (ET-O. we measured urinary excretion of ET-I-like 
immunoreactivity (LI) in 17 patients with renal disease and 9 normal 
subjects. Twenty-four hour urinary ET-I-LI excretion in patients with 
renal disease (358 ± 68 ng, mean ± SE) was significantly (P < 0.005) 
greater than that of normal subjects (77 ± 5 ng). In patients with renal 
disease, ET-I-LI clearance (CET) exceeded creatinine clearance (CCR); 
CET/CCR (305 ± 81%) was significantly (P < 0.005) greater than that of 
normal subjects (43 ± 13%). The 24-hour urinary excretion of ET-I-LI 
in patients with renal disease showed significant correlation with that of 
N-acetyl-f3-D-glucosaminidase (r = 0.587, P < 0.05), f32-microglobulin 
(r = 0.614, P < 0.00 and albumin (r = 0.484, P < 0.05). Intravenous 
infusion of saline (500 ml) in seven normal subjects did not affect 
urinary ET-I excretion rate. These data suggest that urinary excretion 
of ET-I derives mainly from renal tubular secretion at least in patients 
with renal disease, and that degradation and/or reabsorption of ET-I at 
the tubular site may also contribute to the renal handling of ET-l. 
Therefore, urinary excretion of ET -I should serve as a potential marker 
for renal injury. 
Endothelin-l (ET -0 is a 21-residue vasoconstrictor/pressor 
peptide, originally isolated and sequenced from porcine aortic 
endothelial cells [1]. Using a specific radioimmunoassay (RIA) 
for ET-l, we have demonstrated the presence of ET-l-LI in 
human plasma [2] as well as in urine [3]. We have further shown 
that renal epithelial cell lines (LLCPK] and MDCK) also 
synthesize and secrete ET-l-LI into the medium [4]. Assuming 
that ET-l and related peptides are secreted from renal tubular 
cells into the lumen in vivo, the physiological and pathophys-
iological functions of urinary ET -1 need to be elucidated. 
Furthermore, measurement of urinary excretion of N-acetyl-f3-
D-glucosaminidase (NAG), f32-microglobulin (132m), or albumin 
proves to be useful markers to detect tubular and/or glomerular 
disorders [5,6]. Therefore, the present study was designed to 
determine the urinary excretion of ET-l-LI in patients with 
renal disease compared with that of normal subjects. We also 
compared urinary excretion of ET -1-LI with that of NAG, 132m 
and albumin to know whether urinary ET -1 could be a potential 
marker for renal injury. Lastly, we studied whether volume 
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expansion affects urinary excretion rate of ET-l-LI in normal 
subjects. 
Methods 
Subjects 
Nine healthy volunteers (6 men and 3 women; aged 38 ± 6 
years) and 17 patients with renal disease (12 men and 5 women, 
aged 44 ± years) participated in the present study (Table 1) 
Informed consent was obtained from each individual. Renal 
disease consisted of chronic glomerulonephritis (membranous 
proliferative glomerulonephritis, IgA nephropathy, minimal 
change disease, focal glomerulosclerosis), lupus nephritis, renal 
transplantation from cadaver, and end-stage renal disease of 
unknown etiology, as summarized in Table 1. 
Creatinine clearance (CCr) of normal control subjects and 
patients with renal disease were 105 ± 4 (N = 9) and 54 ± 10 (N 
= 17) mllmin/1.73 m2 , respectively. The urinary excretion of 
albumin in normal subjects and patients with renal disease were 
0.005 ± 0.001 and 2.7 ± 0.8 g124 hr, respectively. 
Saline loading 
Saline was infused i.v. for one hour (total volume 500 ml) in 
seven normal subjects (aged 32 ± 2 years). Urine specimens 
were collected for a two hour period before and after saline 
infusion. Blood sampling was performed in the middle of each 
urine collection period. 
Sample collection 
Urine was collected during a complete 24-hour period from 
normal subjects and patients with renal disease. Blood samples 
were simultaneously obtained early in the morning on the day of 
urinary sampling from all normal subjects and 13 patients with 
renal disease. Aliquots of urine and plasma were frozen at 
-40°C until assayed. 
Radioimmunoassay (RIA) of ET-J 
Urinary and plasma ET-l-LI was measured by specific radio-
immunoassay (RIA) as recently described [2,3]. The antibody 
used cross reacted fully with ET-l, 2% with big ET-l and less 
than 0.1% with ET-2 or ET-3. Urine samples were serially 
diluted and assayed. Plasma samples were extracted with 
octadecyl-silica (Spe-Cs, J.T. Baker Chemical Co., Phil-
lipsburg, New Jersey, USA) as described in [3]. The recovery of 
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Table 1. Summary of clinical data in patients with renal disease compared with normal subjects studied 
CCr MAP UFR UN.V UETV CET 
Case Age/Sex Disease mllmin/l.73 m2 mmHg ml/min mEql24 hr ng/24 hr mllminll .73 m2 
1 53/M MPGN 53 130 0.97 92 152 29 
2 56/F MPGN 128 108 1.30 85 98 32 
3 65IM MPGN 21 86 0.77 43 139 
4 201M IgA nephropathy 118 89 0.94 167 164 330 
5 351M IgA nephropathy 69 97 0.83 96 121 
6 64/F IgA nephropathy 26 71 1.53 160 295 46 
7 531F MCD 115 104 0.61 62 74 74 
8 211M MCD lOS 84 1.08 31 65 91 
9 291M MCD 76 117 1.34 163 115 
10 621M FGS 15 147 0.92 89 667 31 
11 371M lupus nephritis 44 128 0.90 60 312 32 
12 46/F lupus nephritis 71 % 1.11 176 512 302 
13 171M end-stage RD 10 103 0.58 42 681 88 
14 47/M end-stage RD 8 114 0.90 61 377 128 
15 251M end-stage RD 7 113 1.01 73 824 61 
16 72/F end-stage RD 5 92 0.63 63 630 
17 35/M transplantation 37 105 3.25 234 860 128 
Mean ± SE 44 ± 4 54 ± lOa 105 ± 5b 1.63 ± 0.55 100 :t 14 358 ± 68" 106 ± 28c 
Normal 38 ± 6 105 ± 4 88 ± 4 0.92 ± 0.14 145 ± 29 77 ± 5 50 ± 18 
(N = 9) (years old) 
Abbreviations are: Ccp creatinine clearance; MAP, mean arterial blood pressure; UFR, urinary flow rate ; UN.V, urinary sodium excretion; 
UETV, urinary ET-I-LI excretion; CET, ET-I-LI clearance; MPGN, membranous proliferative glomerulonephritis; MCD, minimal change disease ; 
FGS, focal glomerulosclerosis; RD, renal disease. 
Significant differences between normal subjects and patients are denoted by 'P < 0.005, bp < 0.025, and cp < 0.05. 
standard ET-I during the extraction procedure was 61.8 ± 3.4% 
(N = 4). In brief, 0.1 ml standard ET-l or sample and 0.1 ml 
antibody (final dilution, 1: 150,000) were pre incubated at 4°C for 
24 hours, followed by the addition of 0.1 ml [125I]ET_l (specific 
activity: 2000 Ci/mmol, Amersham, Japan) and further incu-
bated for 48 hours. Separation of the bound from free ligand 
was accomplished by the double antibody method. The sensi-
tivity of the ET-J RIA was 1 fmol/tube, and the 50% intercept 
was 8 fmol/tube. Intraassay and interassay coefficients of vari-
ations were 6.9% and 7.3%, respectively. 
Determinations of other urinary markers 
Urinary N-acetyl-f3-D-glucosaminidase (NAG), f32-micro-
globulin (132m), and albumin were determined by colorimetric 
analysis, Latex photometric immunoassay, and radioimmuno-
assay, respectively. Urinary and plasma creatinine concentra-
tions were measured by an Autoanalyzer (Hitachi 736 model). 
Statistical analysis 
Values are given as the mean ± standard error (SE) . Statisti-
cal analysis was performed using two sample Wilcoxon test and 
paired t-test. 
Results 
The serial dilution curves generated by urine samples from 
patients with massive proteinuria (2.9-7.9 mg/ml) and normal 
subjects were parallel to that of standard ET-l in RIA (Fig. I), 
suggesting that material(s) immunologically similar, if not iden-
tical, to ET -1 exists in human urine. The percentage of nonspe-
cific binding in the absence of antibody to the total radioactivity 
added into the urine samples from patients with renal disease 
(4.6 ± 0.6%; N = 8) was not different (P > 0.05) from that of 
control samples (5.1 ± 0.2%). The addition of albumin (concen-
trations up to 10 mg/ml) into incubation mixture did not affect 
the binding of [125I]ET_l to its antibody in RIA (data not 
shown). Furthermore, there existed an excellent correlation (r 
= 0.983) between the values in extracted and unextracted urine 
samples [3]. Therefore, the extraction procedure is not required 
for the routine measurement of urinary ET-I-LI. ' 
Patients with renal disease showed a significantly (P < 0.(05) 
greater daily urinary ET-l-LI excretion (358 ± 68 ng) than that 
of normal subjects (77 ± 5 ng; Table 1, Fig. 2A). The clearance 
of ET-l-LI (CET) in normal subjects (50 ± 18 mllmin/1.73 m2) 
was less than CCr (105 ± 4 ml/minl1.73 m2), while CET (106 ± 
28) exceeded CCr (57 ± 13) in 13 patients with renal disease 
(Table 1). As shown in Figure 2B, the calculated ratio of 
ET-l-LI to creatinine clearance (CET/CCr) in renal disease (305 
± 81%) was significantly (P < 0.005) greater than that of normal 
subjects (43 ± 13%). 
The 24-hour urinary excretion of ET-I-LI in patients with 
renal disease showed significant correlations with that of NAG 
(r = 0.587, P < 0.05) , ~m (r = 0.614, P < 0.01) and albumin (r 
= 0.484, P < 0.05 Fig. 3), but not with mean arterial blood 
pressure (r = 0.226), urine flow rate (r = 0.327), or sodium 
excretion (r = 0.204, Table I). 
Intravenous saline infusion in seven normal subjects signifi-
cantly (P < 0.001) increased urine flow rate from 0.92 ± 0.08 to 
1.82 ± 0.18 mllmin as well as sodium excretion rate from 0.17 ± 
0.03 to 0.29 ± 0.03 mEq/min (P < 0.01). Urinary ET-l-LI 
excretion rate before (117 ± 17 pg/min) and after saline infusion 
(133 ± 19 pg/min) did not change (Fig. 4). Neither plasma 
ET-J-LI levels (2.0 ± 0.2 vs. 1.8 ± 0.4 pg/ml) nor CCr (133 ± 6 
vs. 134 ± 10 rnlJmin/1.73 m2) changed during saline infusion. 
Discussion 
The present study confirms our previous observations that 
ET-l-LI is excreted in normal subjects [3], and further shows 
that urinary excretion of ET -1-LI is ~reater in patients with 
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Fig. 1. Dilution curves of human urine in ET-
J RIA. Urine samples (0) obtained from renal 
disease patients with massive proteinuria were 
serially diluted and compared with that of 
standard curve of ET-I (e). ET-l, fmol/tube 
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Fig. 2. Urinary ET-J-LI excretion (A) and the ratio of ET-J-LI clear-
ance to creatinine clearance (B). Patients with renal disease (0) showed 
significantly (* P < 0.005) higher excretion of ET -1-LI and CET/Ccr than 
those of normal subjects (e). 
renal disease than in normal subjects. Results of the present 
study show that high concentrations of albumin did not affect 
the binding of [125I]ET -1 to its antibody, and the fact that 
nonspecific binding of urine samples from patients with renal 
disease did not differ from that of control samples suggests that 
albumin and/or other substance(s) in renal disease patients' 
urine interfers little, if any, in ET-I RIA. The apparent paral-
lelism of the dilution curves of the unextracted urine samples 
from renal disease patients with proteinuria as well as normal 
subjects to that of standard ET -1 in RIA, further strengthens the 
conclusion that ET-l-like material(s) in human urine is immu-
nologically indistinguishable from authentic ET -1. Further-
more, we have already shown that an excellent correlation 
exists between urinary ET-l-LI levels measured directly and 
those after extraction [3]. Therefore, it appears most unlikely 
that increased urinary excretion of ET-l-LI in patients with 
renal disease is simply due to increased excretion of nonspecific 
ET-l-binding material(s). 
In the present study, urinary ET -1-LI excretion rate did not 
change after saline infusion in normal subjects, suggesting that 
urinary ET-l-LI excretion is not influenced by urine volume. 
The ratio of CET/Ccr was less than 100% in all but one normal 
subjects. Should ET -1 be freely filtrable through the glomeruli, 
and all the filtered ET -1 be excreted in the final urine without 
any secretion from or reuptake by the tubules, the ratio of 
CET/Ccr should be 100%. Thus, the present clearance data 
suggest a possible degradative and/or reabsorptive process of 
ET -1 at the tubular level. Our data are consistent with those of 
recent studies in which bilateral nephrectomy of rats leads to 
delayed disappearance of exogenous ET -1 [8] and potentiation 
of its vasoconstriction [9], suggesting the importance of kidney 
as the site of clearance for ET -1. 
In 8 of 13 patients with renal disease, however, the ratio of 
CET/Ccr exceeded 100%. This observation suggests that ET-l 
may be secreted mainly from the renal tubular cells into lumen. 
In fact, we have demonstrated the secretion of ET-I-LI from 
renal tubular cell lines (LLCPK 1 and MDCK) [4], and the 
expression of preproET-l mRNA in the cells [7]. 
The positive, although weak, correlation between urinary 
excretion of ET-J-LI and albumin seems to argue against its 
tubular source, but for its glomerular source. However, urinary 
excretion of NAG with a molecular size of 125,000, that is, too 
large to be filtered, also correlates closely with proteinuria in 
infants with renal disease [10]. In fact, our adult nephrotic 
patients excreted far higher rates of the tubular marker enzyme, 
NAG and protein, 132m than those with normal renal function. 
Furthermore, urinary ET -1-LI excretion in our patients corre-
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Fig. 4. The change of urinary ET-J-Ll excretion rate during saline 
infusion. Uinary ET-I-Ll excretion did not significantly change before 
and after saline (500 ml) infusion in 7 normal subjects. 
lated more closely with that of NAG and ~m than albumin. 
Thus, the mechanism of the increased excretion of urinary 
ET -1-LI similar to that of NAG and 132m might be responsible in 
our nephrotic patients. 
The physiological function of ET -I in the kidney remains 
unknown. It has recently been shown that ET-I inhibits Na+-
K+-ATPase in inner medullary collecting duct [11] as well as 
vasopressin-induced cyclic AMP accumulation in the collecting 
duct r12] of rat kidney. Therefore, it is tempting to speculate 
that ET-l of renal origin may function as a local modulator of 
ion transport/water permeability in renal tubules. Furthermore, 
it has been reported that ET-I acts as a mitogenic factor for 
glomerular mesangial cells [13]. If ET-I also has a mitogenic 
effect on tubular cells, the increased urinary ET-I-L1 in renal 
disease might participate in the healing process of tubular cells, 
such as in glomerulonephritis or interstitial nephritis. It is thus 
significant that several active substances released during coag-
ulation and inflammatory process, such as thrombin, platelet-
derived transforming growth factor-13 and cytokines (tumor 
necrotizing factor-a, interleukin-If3), stimulate ET -1-L1 secre-
tion from renal epithelial cells in culture [7]. Therefore, urinary 
ET-I excretion, like NAG and 132m, may serve as a potential 
marker for renal injury. 
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